Skip to content
Using Computational Discovery to Build Better Immunotherapies episode artwork

Jan 7, 2021 35 min

Using Computational Discovery to Build Better Immunotherapies

from The Bio Report Hosted by Levine Media Group

While checkpoint inhibitors represent a class of promising new therapies to treat cancer, the efficacy of these immunotherapies have been limited because of the ability of cancers to develop resistance. In part, that’s because of the multiple mechanisms cancers have to evade the immune system. Compugen is using a computational discovery platform to identify proteins and pathways that drive immune resistance mechanisms to checkpoint inhibitors. We spoke to Anat Cohen-Dayag, CEO of Compugen, about the company’s discovery platform, its efforts to develop new treatments that address patients who don’t respond to current checkpoint inhibitors, and its clinical pipeline in development.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Using Computational Discovery to Build Better Immunotherapies

0:00 35:51

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 35 minutes long.

When was this The Bio Report episode published?

This episode was published on January 7, 2021.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.